Table 3.
SGLT2 inhibitor or GLP1 receptor agonist use by demographic and clinical subgroups from the integrated health system clinics
| Variable | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | Absolute difference 2013–2019 | 95% confidence interval |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Eligible T2DM Patients (n) | 4522 | 4747 | 4915 | 5103 | 5496 | 6342 | 16422 | – | – |
| Total on SGLT2i or GLP1 RA (n) | 495 | 742 | 1059 | 1135 | 1302 | 1639 | 3539 | – | – |
|
| |||||||||
| Prescription of SGLT2 inhibitor or GLP1 receptor agonist by select patient demographics and clinical characteristics (%) * | |||||||||
|
| |||||||||
| Sex | |||||||||
| Female | 11% | 16% | 22% | 22% | 23% | 26% | 20% | 9% | 7%–11% |
| Male | 11% | 15% | 22% | 22% | 24% | 26% | 23% | 12% | 10%–14% |
| Race/ethnicity | |||||||||
| Non-Hispanic White | 13% | 19% | 23% | 24% | 25% | 27% | 22% | 9% | 7%–11% |
| Non-Hispanic Black | 6% | 9% | 18% | 16% | 15% | 20% | 18% | 12% | 9%–15% |
| Hispanic | 9% | 13% | 19% | 21% | 22% | 25% | 21% | 12% | 8%–16% |
| Non-Hispanic Asian | 5% | 8% | 17% | 21% | 21% | 22% | 19% | 14% | 9%–19% |
| Other | 9% | 13% | 17% | 20% | 23% | 25% | 19% | 10% | 5%–16% |
| Hemoglobin A1c Level | |||||||||
| 7.0–9.9% | 16% | 22% | 29% | 29% | 31% | 33% | 30% | 14% | 12%–16% |
| 10.0–12.9% | 14% | 25% | 33% | 35% | 36% | 38% | 34% | 20% | 14%–26% |
| >/=13.0% | 4% | 23% | 23% | 21% | 21% | 28% | 29% | 25% | 14%–36% |
| Heart Failure (EF%) | |||||||||
| > 50% | 4% | 6% | 7% | 8% | 12% | 15% | 13% | 9% | 4%–14% |
| 40%–49% | 4% | 8% | 13% | 6% | 14% | 13% | 8% | 4% | −7%–15% |
| < 40% | 2% | 4% | 5% | 5% | 7% | 10% | 15% | 13% | 6%–20% |
| Missing EF | 8% | 9% | 10% | 10% | 9% | 11% | 15% | 7% | 2%–12% |
| Chronic kidney disease† | |||||||||
| GFR < 60 mL/min/1.73m2 | 4% | 7% | 11% | 12% | 15% | 17% | 17% | 13% | 10%–16% |
| GFR >/= 60 mL/min/1.73m2 | 11% | 16% | 24% | 25% | 25% | 27% | 23% | 12% | 10%–14% |
Usage rates equal the number of medication users divided by the total eligible in each category per year.
EF = ejection fraction; GFR = glomerular filtration rate; T2DM = type 2 diabetes mellitus.
*
There were a variable number of patients missing data for certain categories ranging from 8% to 30%; missing patients were excluded from the analysis.
†
GFR was calculated using the Modification of Diet in Renal Disease equation.